Research Funding. (a) During each Collaboration Term and in connection with any wind-down activities contemplated by Section 13.4. Gilead shall reimburse Hookipa for all Out-of-Pocket Costs actually incurred (with no markup) by Hookipa in connection with the applicable Program, to the extent specifically contemplated in the applicable Research Plan and in accordance with the applicable Research Budget. Gilead shall reimburse the undisputed amount of such Out-of-Pocket Costs incurred in a [***] within [***] days after receipt from Hookipa of an invoice therefor issued within [***] days after the end of such [***].
(b) During each Collaboration Term for a Program, Gilead shall reimburse Hookipa at the FTE Rate for the costs of any FTEs (not to exceed the number of FTEs specified in the applicable Research Plan for such Program for any period without first obtaining, in each case, Gilead’s prior written consent) actually performing activities allocated to Hookipa under such Research Plan. Hookipa shall provide to Gilead, within [***] days after the end of each [***] during each Collaboration Term, a report indicating the number of FTEs actually provided by Hookipa with respect to each Program during such [***], Hookipa shall use standard industry systems and processes to record the number of hours and FTEs actually applied to each Program, which systems and processes shall be consistently and equitably applied to all Hookipa research programs with Third Parties. Gilead shall reimburse Hookipa the undisputed amount for such FTE costs incurred in a [***] within [***] days after receipt from Hookipa of an invoice therefor issued within [***] days after the end of each [***].
(c) For clarity, Gilead shall not be obligated to reimburse Hookipa for any costs or expenses incurred by Hookipa in the course of its activities under the Programs, other than: (i) those costs and expenses expressly identified in this Section 9.6 or elsewhere in this Agreement; (ii) reimbursement for the supply of Licensed Products to Gilead in accordance with the terms of any supply agreement entered into by the Parties pursuant to Section 7.2; or (iii) any other costs and expenses approved by Gilead in writing in advance.
Research Funding. Arsanis shall compensate Adimab on a calendar quarterly basis for Adimab’s performance of its obligations under, and in accordance with, the Research Plan, in an amount determined by multiplying the actual FTEs expended by Adimab in the performance of such obligations during such calendar quarter by the FTE Rate. Adimab shall issue quarterly written invoices to Arsanis setting forth the actual FTEs expended by Adimab in performing such Research Plan obligations, which invoice shall describe the Research Plan activities performed, and Arsanis shall pay the invoiced amount within [**] days of receipt.
Research Funding. Subject to Sections 12.2 and 12.3, for the first two (2) years of this Agreement, PDL shall make research funding and license payments totaling four million dollars ($4,000,000) per year. This initial Research Term shall be deemed to begin on [ * ]. Research Funding shall be payable in equal [ * ] installments within [ * ] after the beginning of each [ * ] during the term of the Research Funding. The annual Research Funding at the rate of four million dollars ($4,000,000) per year shall be [ * ]. If the Research Term has been [ * ], then the research funding shall [ * ] at the rate of [ * ] for the following [ * ]. The Research Term and Research Funding thereafter shall be [ * ] at the rate of four million dollars ($4,000,000) per year for the [ * ].
Research Funding. During each year of the Research Term (as it may be extended), Wyeth shall pay Trubion *** per year for services performed in accordance with the Research Plan. Trubion shall commit to the Research Program ten (10) FTEs per year to provide services in furtherance of the Research Program in accordance with the Research Plan. For the avoidance of doubt, Trubion may, at its sole expense and discretion, devote more than *** FTEs from time to time to provide services in furtherance of the Research Program. The *** in research funding described above shall be increased automatically once per calendar year by the percentage change in the U.S. Consumer Price Index, All Urban Consumers over the previous year; provided, however, that no increase shall be effective prior to January 1, 2007. ***. Trubion shall provide to Wyeth, prior to the first day of each Calendar Quarter, a forecast of such expenses (by major expense category, on an accrual basis) reimbursable under this Section 3.6.1 which Trubion expects to incur during such Calendar Quarter and the subsequent three Calendar Quarters, in each case shown by month. Other than the foregoing amounts and except as otherwise expressly provided in this Agreement, each Party shall be solely responsible for its costs and expenses incurred in performing its obligations under the Research Program.
Research Funding. LICENSEE shall provide research funding to [****] lab at MSK (or a successor lab reasonably acceptable to the Company at MSK if [****] lab at MSK is no longer operating) equaling at least one million three hundred and sixty-two thousand and eighty-five dollars ($1,362,085) including a [****] overhead for indirect costs (over two (2) years immediately following the Effective Date of this Agreement in accordance with the budget generated by MSK to be incorporated into the Sponsored Research Agreement.
Research Funding. (a) In addition to the payments contemplated under Sections 5 and 6 hereof, Syngenta agrees to pay Diversa for FTEs for Directed Research and Project Research (the “FTE Funding”) $20.665 million per annum for the initial five year term of the Research Term under this Agreement. The cost of the Directed Research and the Project Research to be funded by Syngenta shall be calculated based on the number of FTEs allocated to such work at the following rates for the 2003 calendar year: $[…***…] per annum for FTEs engaged in Project Research (the “Project Research Rate”); and $[…***…] per annum for FTEs engaged in Directed Research (the “Directed Research Rate”). The Project Research Rate and the Directed Research Rate for each FTE shall be CPI adjusted on the annual anniversary of the Effective Date, applying the published CPI figure as of October 31 of the prior year, using 2002 as the base year; provided, however, that in no event shall the Project Research Rate or the Directed Research Rate be reduced. The first CPI adjustment will be for the 2004 Year and will be based on the CPI as of October 31, 2003. If CPI adjustments result in increases in the FTE Funding rate such that the total FTE Funding under this Section 2.6(a) would exceed $20.665 million per annum during any Year, Syngenta may, with reasonable notice to the Research Committee, modify that Year’s Research Plan so as to (i) increase its FTE Funding to maintain the same number of FTEs, or (ii) reduce the number of FTEs, as necessary, to limit its annual FTE Funding to $20.665 million per year.
(b) Subject to Section 12.1, for any period of this Agreement beyond the initial five years of the Research Term, Syngenta may fund Directed Research and Project Research at any level of funding in its discretion, as set forth in the provisions of this Section 2.6(b); provided, however, Syngenta must give Diversa at least […***…] notice of extension of the Research Term under this Agreement prior to the expiration of any current Research Term, including the level of FTE Funding during such extension. For purposes of the following provisions, “T” means the last year of the Research Term in which FTE Funding was at least $20.665 million. If Syngenta elects to reduce the FTE Funding in any year after the initial five year Research Term from the prior year’s FTE Funding, it may reduce FTE Funding up to a maximum of 50% of T in the first year of reduction; up to a maximum reduction of 75% of T in the second year; ...
Research Funding. At each DECISION POINT for each PROJECT, RWJPRI shall have the right to elect whether to proceed with the CONTINGENT WORK for such PROJECT consequent to such DECISION POINT. It is understood and agreed that RWJPRI must provide RESEARCH FUNDING as set forth in the RESEARCH PLAN until at least the second anniversary of the EFFECTIVE DATE subject to the provisions of Article 19. RWJPRI shall provide RESEARCH FUNDING (i) for the Fast Track PROJECT, until the earlier of (a) identification of a [**] as an NCE in the Fast Track PROJECT ("N1" in Exhibit A) or (b) twelve (12) months from the EFFECTIVE DATE, and (ii) for the SAR PROJECT, until the earlier of (x) identification of [**] as NCEs in the SAR PROJECT ("N2" and "N3" in Exhibit A) or (y) twenty-four (24) months from the EFFECTIVE DATE. [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
Research Funding. GSK shall make non-refundable, non-creditable payments (the “Research Payments”) to EPIZYME for activities to be undertaken by EPIZYME under the Research Plans as follows:
(a) Commencing on the first (1st) anniversary of the Effective Date and the date that is the first day of each Calendar Quarter after the first anniversary of the Effective Date, GSK shall pay equal Calendar Quarterly installments of Seven Hundred Fifty Thousand Dollars ($750,000.00) to EPIZYME for eight (8) consecutive Calendar Quarters (with the first such Calendar Quarterly installment being due on the first anniversary of the Effective Date). For illustrative purposes only, if the Effective Date of the Agreement is January 8, 2011, then the first Research Payment would become due on January 8, 2012, and the second Research Payment would become due on April 1, 2012.
(b) Commencing on the third (3rd) anniversary of the Effective Date and on the date that is the first day of each Calendar Quarter of the fourth (4th) year of the Research Term, GSK shall pay to EPIZYME advance Calendar Quarterly installments constituting the portion of the total FTE Costs and Out-of-Pocket Costs budgeted for such Calendar Quarter under the Research Plans pursuant to Section 2.3.3 (with the first such Calendar Quarterly installment being due on the third (3rd) anniversary of the Effective Date). Within [**] days following the end of the Research Term, the Parties shall conduct a reconciliation of actual FTE Costs and Out-of-Pocket Costs incurred by EPIZYME for activities conducted during the fourth (4th) year of the Research Term against the amount budgeted for such fourth (4th) year, and the Parties shall true up actual FTE Costs and Out-of-Pocket Costs to budgeted amounts, within [**] percent ([**]%) of the amount budgeted, for the fourth (4th) year of the Research Term through an appropriate reconciliation payment so that GSK’s research funding payments to EPIZYME with respect to the fourth (4th) year of the Research Term, net of such reconciliation payment, equal the actual FTE Costs and Out-of-Pocket Costs incurred by EPIZYME for activities conducted during the fourth (4th) year of the Research Term (but not more than [**]% of the budgeted amount). If EPIZYME determines it cannot complete the activities set forth in the Research Plans for the fourth (4th) year of the Research Term within [**] percent ([**]%) of the budgeted amounts, EPIZYME shall promptly notify GSK and, provided that such inability i...
Research Funding. 11 2.12 Materials ....................................................... 12 2.12.01
Research Funding. 5.1 In consideration of the performance by Protagonist of its obligations under the Research Plan, Zealand shall pay Protagonist a sum of [*] (the “Research Funding”). The Research Funding shall be due as follows:
5.1.1 [*] on the Effective Date; and
5.1.2 [*] on [*].
5.2 The Research Funding shall be non-refundable, non-rebateable and non-creditable.
5.3 The Research Funding is paid on the basis of Protagonist committing a total of a maximum of [*] full time equivalents for a maximum of [*] Research Term for the Zealand Target. Such Research Funding is fully loaded, and Zealand shall not be required to make any further payment to Protagonist in relation to personnel, facilities, equipment, consumables and overheads except as set forth in Section 5.4, provided however, Zealand shall be responsible, in addition to the Research Funding, for:
5.3.1 the costs of any [*] not conducted by Zealand to the extent such [*] is required under the Research Plan; and
5.3.2 any reasonable and properly substantiated costs incurred by Protagonist to [*] related to the Zealand Target which are not provided by Zealand in accordance with the amounts, quality or timetable as set out in the Research Plan; and
5.3.3 any reasonable and properly substantiated costs incurred by Protagonist [*] for the performance of the activities under the Research Plan; provided both [*] and the costs associated [*] is either included in the Research Plan or approved by Zealand.
5.4 In the event that the performance as provided herein of the Research Plan with respect to the Initial Development Program requires services from Protagonist after [*], the amount payable by Zealand to Protagonist with respect to such services shall be calculated on the basis of Protagonist committing a total of a maximum of [*] full time equivalents payable at a full time equivalent rate of [*] per FTE per annum and Protagonist shall invoice Zealand monthly with respect to such services at such rate. In the event that the performance as provided herein of the Research Plan with respect to the Initial Development Program requires services from Protagonist after [*], the amount payable by Zealand to Protagonist with respect to such services shall be calculated on the basis of the Adjusted Protagonist FTE Rate, and Protagonist shall [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 o...
